Operations at ANI Pharmaceuticals’ manufacturing plant in Oakville, Ontario, are expected to cease by Q1 2023 as part of ongoing initiatives to “capture operational synergies” following the company’s acquisition of niche generics firm Novitium Pharma.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?